Tacrolimus ointment for the treatment of atopic dermatitis.
(1) Atopic dermatitis (AD) is a chronic dermatological condition characterized by pruritus (itchiness) and rash. Topical corticosteroids are the mainstay of pharmacotherapy. (2) Tacrolimus ointment is a new topical anti-inflammatory agent available in Canada through the Special Access Program. (3) It is approved as a second line agent for short or long term intermittent treatment of moderate to severe AD. (4) Clinical trials suggest it is both effective and safe, but comparative studies with corticosteroids and long-term information are limited.
Boucher
M
M
D002170:Canada; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use; D007564:Japan; D016559:Tacrolimus / Q000191:economics / Q000627:therapeutic use*; D013673:Technology Assessment, Biomedical; D014481:United States; D014486:United States Food and Drug Administration
D007166:Immunosuppressive Agents; D016559:Tacrolimus